slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 98,161-98,190
Pages 3,953
Rows per page 30
Component
98,161-98,190 of 118,578
25
Includes a process diagram showing inputs (models, schedules, ERP), constraints, and outputs (maps, timelines, charts).Bigbear AI | Investor Presentation Deck | 29 slides · BigBear.ai
Pitch deck Investor relations 1 hit
09
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
18
The slide uses a process-oriented layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Traction1 hit
24
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
25
The slide uses a combination of high-level market statistics and specific clinical benchmarks to define the target opportunity.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
26
The chart highlights a specific patient case with a partial response (PR) and notes a suboptimal dose case.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
27
Uses a 2x2 grid of metrics to frame the problem space.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
29
The slide uses a funnel-like logic to narrow down from total prevalence to a specific addressable patient population for a 2L+ therapy.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
30
The slide uses a table to present clinical trial outcomes (PR/CR) and safety data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
35
The slide uses a combination of a summary table for clinical endpoints and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
37
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
39
The slide uses a process flow diagram to illustrate dose escalation strategies (Accelerated vs Standard vs Priming).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
40
The slide uses a two-column layout to represent 1H and 2H of 2023.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
04
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a central white box overlay on a split-image background (food scene and delivery scene).Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
10
The slide highlights both year-over-year and quarter-over-quarter margin growth.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
14
Includes specific financial targets related to rebates, cash consideration, and seller notes.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations 1 hit
01
Blue Apron | Results Presentation Deck | 24 slidesBlue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations 1 hit
04
Blue Apron | Results Presentation Deck | 24 slidesBlue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations 1 hit
07
The slide uses a culinary-themed background, likely reflecting the company's industry (food/grocery).Blue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations Beat · AttentionLoop · Cost Of Inaction1 hit
11
Blue Apron | Results Presentation Deck | 24 slidesBlue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The chart displays a dual-axis style visualization (bar for revenue, line for customers) within a single plot area.Blue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
15
The Q2 '23 Net Loss bar includes a specific footnote regarding the FreshRealm transaction impact.Blue Apron | Results Presentation Deck | 24 slides · Blue Apron
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
01
The slide features a high-quality stock photo of a clinician in a hospital setting, establishing the context of critical care.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations 1 hit
03
The slide uses a horizontal list format to present five key pillars of the company's business model.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations 1 hit
05
The slide uses a process diagram to contrast current clinical workflows with the proposed solution, followed by a bar chart illustrating the exponential mortality risk over time.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a problem-solution framing, identifying the 'why' (IL-6 is good) and the 'but' (it's unstable), leading to the company's value proposition at the bottom.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The table provides a bottom-up calculation of TAM based on patient volume, test frequency, and pricing, with a projected uplift from the company's product.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
11
The table highlights NPV as the key differentiator. The ROC chart visually confirms IL-6's superior AUC.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit